Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases
- 15 January 2022
- journal article
- research article
- Published by Springer Nature in Drugs
- Vol. 82 (3) , 311-322
Abstract
Introduction Whether metformin reduces all-cause cardiovascular mortality and the incidence of cardiovascular events in patients with pre-existing cardiovascular diseases (CVD) remains inconclusive. Some randomised controlled trials (RCTs) and cohort studies have shown that metformin is associated with an increased risk of mortality and cardiovascular events. Methods We conducted a pooling synthesis to assess the effects of metformin in all-cause cardiovascular mortality and incidence of cardiovascular events in patients with CVD. Studies published up to October 2021 in PubMed or Embase with a registration in PROSPERO (CRD42020189905) were collected. Both RCT and cohort studies were included. Hazard ratios (HR) with 95% CI were pooled across various trials using the random-effects model. Results This study enrolled 35 published studies (in 14 publications) for qualitative synthesis and identified 33 studies (published in 26 publications) for quantitative analysis. We analysed a total of 61,704 patients, among them 58,271 patients were used to calculate all-cause mortality while 12,814 patients were used to calculate cardiovascular mortality. Compared with non-metformin control, metformin usage is associated with a reduction in all-cause mortality (HR: 0.90; 95% CI 0.83, 0.98; p = 0.01), cardiovascular mortality (HR: 0.89; 95% CI 0.85, 0.94; p < 0.0001), incidence of coronary revascularisation (HR: 0.79; 95% CI 0.64, 0.98; p = 0.03), and heart failure (HR: 0.90; 95% CI 0.87, 0.94; p < 0.0001) in patients with pre-existing cardiovascular diseases. Conclusion Metformin use is associated with a reduction in all-cause mortality, cardiovascular mortality, incidence of coronary revascularisation, and heart failure in patients with CVD; however, metformin usage was not associated with reduction in the incidence of myocardial infarction, angina, or stroke.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (91749108, 31671424, 31571413)
- Major Research and Invention Plan of Shaanxi Province, China (2018SF-270, 2018SF-101)
This publication has 83 references indexed in Scilit:
- Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled TrialsPLOS Medicine, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Chronic Pretreatment of Metformin is Associated with the Reduction of the No‐Reflow Phenomenon in Patients with Diabetes Mellitus After Primary Angioplasty for Acute Myocardial InfarctionCardiovascular Therapeutics, 2011
- Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart FailureCirculation: Heart Failure, 2011
- Metformin Therapy and Outcomes in Patients With Advanced Systolic Heart Failure and DiabetesJournal of Cardiac Failure, 2010
- Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort studyCardiovascular Diabetology, 2010
- A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery DiseaseNew England Journal of Medicine, 2009
- Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical realityTrials, 2009
- Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous interventionThe American Journal of Cardiology, 2004
- Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitusThe American Journal of Cardiology, 1991